Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Top Cited Papers
- 1 August 2009
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (22) , 3584-3590
- https://doi.org/10.1200/jco.2008.20.1293
Abstract
Purpose A randomized, phase III trial demonstrated superiority of sunitinib over interferon alfa (IFN-α) in progression-free survival (primary end point) as first-line treatment for metastatic rena...Keywords
This publication has 11 references indexed in Scilit:
- Quality of Life in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib or Interferon Alfa: Results From a Phase III Randomized TrialJournal of Clinical Oncology, 2008
- Sunitinib Efficacy Against Advanced Renal Cell CarcinomaJournal of Urology, 2007
- Sunitinib: From Rational Design to Clinical EfficacyJournal of Clinical Oncology, 2007
- Sunitinib versus Interferon Alfa in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2007
- Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With SunitinibJNCI Journal of the National Cancer Institute, 2007
- Hypothyroidism after Sunitinib Treatment for Patients with Gastrointestinal Stromal TumorsAnnals of Internal Medicine, 2006
- Sunitinib in Patients With Metastatic Renal Cell CarcinomaJAMA, 2006
- Interferon-Alfa as a Comparative Treatment for Clinical Trials of New Therapies Against Advanced Renal Cell CarcinomaJournal of Clinical Oncology, 2002
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Modelling Survival Data in Medical ResearchPublished by Springer Nature ,1994